- In June 2023, Croda, Inc. announced the initiation of constructing a new manufacturing facility in Pennsylvania, U.S. This strategic investment is aimed at enhancing their production capabilities, ensuring they can effectively meet the evolving demands of the industry. The new facility is expected to strengthen Croda’s position in the market by increasing its manufacturing capacity and improving operational efficiency in response to consumer and industry needs
- In September 2022, Nutriventia, a global player in connecting suppliers and buyers of food, health, and natural ingredients, launched Prolanza, a sustained-release ashwagandha (Withania somnifera) extract. Prolanza is designed to provide prolonged stress management support, offering a new, cutting-edge solution for stress relief. The root-only extract represents an innovative approach to delivering the benefits of ashwagandha over an extended period, meeting consumer demands for functional ingredients
- In February 2022, Biohaven Pharmaceutical Holding Company Ltd., in collaboration with Pfizer Inc., expressed confidence in the potential of rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. The companies have endorsed the 75 mg dose of rimegepant, available as an orally dissolving tablet, for marketing authorization. This medication is expected to offer significant advancements in migraine treatment by targeting the underlying causes and providing better relief for patients suffering from this condition
- In February 2021, DuPont completed its merger of the Nutrition & Biosciences Business with International Flavors & Fragrances, a move that significantly expanded its product offerings. The inclusion of Aquacoat products into DuPont’s portfolio enhances its ability to provide diverse and innovative solutions. This merger allowed DuPont to cater to a broader range of industry needs, further strengthening its position in the market and its capacity to meet customer demands in nutrition and biosciences
